Lv46
580 积分 2024-10-21 加入
IL-17A inhibition by secukinumab induces early clinical, histopathologic, and molecular resolution of psoriasis
23天前
已完结
The risk of malignancy in patients with secukinumab‐treated psoriasis, psoriatic arthritis and ankylosing spondylitis
1个月前
已完结
A multicenter, randomized, double-blinded, placebo-controlled, phase Ⅲ study evaluating the efficacy and safety of Xeligekimab (GR1501) in patients with moderate-to-severe plaque psoriasis
2个月前
已完结
Secukinumab demonstrates high efficacy and a favorable safety profile over 52 weeks in Chinese patients with moderate to severe plaque psoriasis
2个月前
已完结
Current treatment of Psoriasis triggered by Cytokine Storm and future immunomodulation strategies
5个月前
已完结
皖公网安备34019202002308
